Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Anavex Life Sciences stock | $12.45

Learn how to easily invest in Anavex Life Sciences stock.

Anavex Life Sciences Corp is a biotechnology business based in the US. Anavex Life Sciences shares (AVXL) are listed on the NASDAQ and all prices are listed in US Dollars. Anavex Life Sciences employs 20 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Anavex Life Sciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVXL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Anavex Life Sciences stock price (NASDAQ: AVXL)

Use our graph to track the performance of AVXL stocks over time.

Anavex Life Sciences shares at a glance

Information last updated 2021-07-30.
Latest market close$12.45
52-week range$3.65 - $31.50
50-day moving average $22.54
200-day moving average $14.60
Wall St. target price$36.35
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.60

Buy Anavex Life Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Anavex Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anavex Life Sciences price performance over time

Historical closes compared with the close of $12.45 from 2021-05-28

1 week (2021-07-24) N/A
1 month (2021-07-02) -49.35%
3 months (2021-05-04) 5.69%
6 months (2021-01-31) N/A
1 year (2020-07-31) N/A
2 years (2019-07-31) N/A
3 years (2018-07-31) N/A
5 years (2016-07-31) N/A

Anavex Life Sciences financials

Gross profit TTM $0
Return on assets TTM -31.66%
Return on equity TTM -56.58%
Profit margin 0%
Book value $1.08
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Anavex Life Sciences shares

There are currently 7.6 million Anavex Life Sciences shares held short by investors – that's known as Anavex Life Sciences's "short interest". This figure is 13.3% down from 8.8 million last month.

There are a few different ways that this level of interest in shorting Anavex Life Sciences shares can be evaluated.

Anavex Life Sciences's "short interest ratio" (SIR)

Anavex Life Sciences's "short interest ratio" (SIR) is the quantity of Anavex Life Sciences shares currently shorted divided by the average quantity of Anavex Life Sciences shares traded daily (recently around 4.6 million). Anavex Life Sciences's SIR currently stands at 1.66. In other words for every 100,000 Anavex Life Sciences shares traded daily on the market, roughly 1660 shares are currently held short.

However Anavex Life Sciences's short interest can also be evaluated against the total number of Anavex Life Sciences shares, or, against the total number of tradable Anavex Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anavex Life Sciences's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Anavex Life Sciences shares in existence, roughly 110 shares are currently held short) or 0.1122% of the tradable shares (for every 100,000 tradable Anavex Life Sciences shares, roughly 112 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Anavex Life Sciences.

Find out more about how you can short Anavex Life Sciences stock.

Anavex Life Sciences share dividends

We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.

Have Anavex Life Sciences's shares ever split?

Anavex Life Sciences's shares were split on a 1:4 basis on 6 October 2015. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.

Anavex Life Sciences share price volatility

Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $3.654 up to $31.5. A popular way to gauge a stock's volatility is its "beta".

AVXL.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.6697. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).

Anavex Life Sciences overview

Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York. .

Stocks similar to Anavex Life Sciences

Frequently asked questions

What percentage of Anavex Life Sciences is owned by insiders or institutions?
Currently 3.363% of Anavex Life Sciences shares are held by insiders and 26.034% by institutions.
How many people work for Anavex Life Sciences?
Latest data suggests 20 work at Anavex Life Sciences.
When does the fiscal year end for Anavex Life Sciences?
Anavex Life Sciences's fiscal year ends in September.
Where is Anavex Life Sciences based?
Anavex Life Sciences's address is: 51 West 52nd Street, New York, NY, United States, 10019
What is Anavex Life Sciences's ISIN number?
Anavex Life Sciences's international securities identification number is: US0327973006
What is Anavex Life Sciences's CUSIP number?
Anavex Life Sciences's Committee on Uniform Securities Identification Procedures number is: 032797102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site